Study on the association between the polymorphism of MCP-1 rs1024611 and the genetic susceptibility of type 2 diabetes with sepsis

Yan Li, MMa, Junbing He, MMb, Yi-ming Shao, MDc, Lanchun Chen, MMd, Ming Li, MMd, Donghui Tang, MMb, Zhizhou Shi, MMf, Qinghui Liao, MMd, Zhongqiu Guo, MMb, Juan Wang, MBBSg, Qiaoan Zheng, MMb, Yanni Zhao, MMb, Yuhua Chen, MMa,*

Abstract
Monocyte chemoattractant protein-1 (MCP-1) rs1024611 (-2518 A > G) polymorphism are associated with inflammatory diseases. In this study, we investigate the relationship between MCP-1 rs1024611 polymorphism and genetic susceptibility of type 2 diabetes mellitus (T2DM) with sepsis.

Two hundred eighty-five patients with T2DM are divided into the diabetes with sepsis group (combined group, 113 cases) and the diabetes group (172 cases). Blood samples and corresponding clinical data were collected. MCP-1 rs1024611 polymorphism in blood samples was detected by pyrosequencing. Meanwhile, the expressions of MCP-1, tumor necrosis factor-alpha (TNF-α), interleukin (IL)-1β, and IL-6 in blood samples were detected by real-time quantitative polymerase chain reaction and enzyme-linked immunosorbent assay, respectively. The relationship between different genotypes of MCP-1 rs1024611 polymorphic locus and T2DM with sepsis was analyzed by combining with the clinical data of the patients.

The frequencies of rs1024611 AG/GG genotypes and G allele in T2DM with sepsis group were significantly higher than those in T2DM patients without sepsis (P = .004 for AG/GG vs AA genotypes; P = .037 for G allele vs A allele). Subgroup analysis showed that the rs1024611 G allele frequency in the septic shock group was significantly higher than the general sepsis group (P = .02). The expressions of MCP-1 and TNF-α in GG genotypes in T2DM with sepsis group were significantly higher than AA or GA genotypes (P < .05).

This study preliminarily showed that the rs1024611 A > G polymorphism within the promoter region of MCP-1 gene can upregulate the expression of MCP-1 gene and proinflammatory cytokine TNF-α, which ultimately contributed to the predisposition and progression of T2DM with sepsis.

Abbreviations: CCL2 = CC motif chemokine ligand, IL-1β = interleukin-1 beta, IL-6 = interleukin-6, MCP-1 = monocyte chemoattractant protein-1, PCR = polymerase chain reaction, SD = standard deviation, SNP = single-nucleotide polymorphism, T2DM = type 2 diabetes mellitus, TNF-α = tumor necrosis factor-alpha.

Keyword: MCP-1, polymorphism, sepsis, type 2 diabetes mellitus
1. Introduction

Type 2 diabetes mellitus (T2DM), a group of metabolic diseases characterized by insulin resistance and hyperglycemia, is caused by progressive failure of pancreatic islet B cell function. Diabetes-associated infection is a common complication of diabetes and an important cause of death from diabetes.\(^1,2\) Sepsis is a complex clinical syndrome caused by the interaction between the infectious pathogen and the host immune system, inflammatory response, and blood coagulation response, which causes damage to multiple organ functions.\(^3\) It is reported that about 17% of patients with sepsis have DM,\(^4\) which may be an important coexisting disease of sepsis.

It has been demonstrated that diabetic patients exhibited an increased risk of developing infection in sepsis and constituted 20.1% to 22.7% of all sepsis patients.\(^5\) Increased rates of colonization by resistant pathogens (e.g., methicillin-resistant *Staphylococcus aureus*) were found in diabetic patients than nondiabetics.\(^6\) Furthermore, sepsis patients with DM possessed more worse deformability of red blood cells, microcirculation, and organ dysfunction than sepsis patients without DM.\(^7,8\)

Importantly, several lines of studies showed that having DM worsened clinical prognosis of septic patients, as presented by higher sepsis mortality.\(^9\) Monocyte chemotactic protein-1 (MCP-1), also known as CC motif chemokine ligand 2, is a member of the CC subfamily (also known as \(\beta\) subfamily) of chemokines, which is mainly chemotactic on the cell surface. The combination of factor receptor 4 (CCR4) and CCR2 activates the signal transduction pathway and plays an important role in the pathophysiological mechanism of diabetes and sepsis.\(^10\)\(^-\)\(^12\)

The human MCP-1 gene with a genomic region of 79 kb is located on chromosome 17q11.2-q12, which encodes a protein of 76 amino acids. Several studies have shown rs2857636 and rs4586 as MCP-1 functional polymorphisms to affect MCP-1 expression, leading to the susceptibility to pulmonary tuberculosis, spinal tuberculosis, and chronic obstructive pulmonary disease.\(^13\)\(^-\)\(^15\) Another functional genetic polymorphism at rs1024611 (-2518 A > G) in the promoter region of MCP-1 gene affects the expression level of MCP-1 and is associated with a variety of inflammatory diseases. MCP-1 rs1024611 (-2518 A > G) polymorphism can affect the transcriptional activity of MCP-1 and is related to the susceptibility of diabetic foot ulcers, inflammatory bowel disease, and sepsis.\(^16\)\(^-\)\(^18\) However, the relationship between MCP-1 gene polymorphism and diabetes with sepsis is still unclear. This study aimed to analyze the correlation between MCP-1 rs1024611 (-2518 A > G) gene polymorphism and the onset and development of T2DM with sepsis.

2. Methods

2.1. Objects and groups

In this study, a hospital-based case–control study method was used to enroll 285 subjects. Observation group: in accordance with the 2016 International Sepsis Guidelines Sepsis 3.0 Standard, the sepsis group is divided into 2 subgroups: general sepsis group (67 cases) and septic shock group (46 cases).

2.2. Detection of the genotype of the polymorphic site of the target gene

In this study, the SNaPshot method (Shanghai Tianhao Biotechnology Co., Ltd) was used to detect the genotype of the sample MCP-1 rs1024611. The blood genomic DNA was extracted using a whole blood DNA kit (TIANamp), and the purity of the extracted DNA was tested with gel electrophoresis andEpoch spectrophotometer. The ABI 3130xl DNA gene sequence analyzer (ABI, CA) was used to detect the genotype information of the MCP-1 gene polymorphism site. The primer sequences are as follows: rs1024611F, 5\'-u697'-TCTTACCGC-CAGCAGTGACCGTCTAGT673; rs1024611R, 5\'-u697'-CCATT-AAGGGCCCATGTCACAGA-3\'; Power analysis with QUANTO 2.5 software showed 98.0% power for rs1024611 to detect a relative risk difference between genotypes at the significance level of 0.05 and an odds ratio of 2.0 according to our sample size.

2.3. Real-time fluorescence quantitative polymerase chain reaction method to detect target gene expression level

Total RNA was extracted from peripheral blood single cells. Human MCP-1, GAPDH primers were designed and synthesized by Shanghai Shenggong Biological Company. Reverse translation of RNA to cDNA was performed by using the RevertAid\(^\text{TM}\) First Strand cDNA Synthesis Kit (Termo Fisher Scientific). Then SYBR Green mix (Takara) was used for quantitative real-time polymerase chain reaction reaction in an ABI7500 real-time polymerase chain reaction system (Applied Biosystems). GAPDH was used as an internal reference, and the \(2^{-\Delta\Delta Ct}\) method was adapted to analyze gene expression differences. The detected primer sequences are as follows: MCP-1 upstream primer 5\'-u697'-TCTCCTCTCAGCGATGAATTG3\'; downstream primer 5\'-u697'-GGTGACTCGGGGATGTGAGTTG3\'; GAPDH upstream primer 5\'-u697'-CTGACACACCCGACCACGC-3\'; downstream primer 5\'-u697'-GTGGCCACGGGTCTTACTG-3\'.

2.4. Enzyme-linked immunosorbent assay detects the expression levels of TNF-\(\alpha\), IL-1\(\beta\), and IL-6 in blood samples

The levels of tumor necrosis factor-alpha (TNF-\(\alpha\)), interleukin-1 beta (IL-1\(\beta\)), and interleukin-6 (IL-6) in plasma were detected with enzyme-linked immunosorbent assay kit (Boster Biological Technology Co., Ltd, Wuhan, China) using the double antibody sandwich method according to the instructions. The minimum detectable concentrations of TNF-\(\alpha\), IL-1\(\beta\), and IL-6 were all 1 pg/mL. Combined with rs1024611 genotyping data, the blood levels of TNF-\(\alpha\), IL-6, and IL-1\(\beta\) in individuals with different genotypes were compared, and the test results were statistically analyzed.

2.5. Statistical analyses

The experimental data were statistically analyzed using SPSS Version 20.0 software. The Hardy–Weinberg equilibrium was performed to detect the deviation of genotype/allele frequency in the control and sepsis groups. Power analysis with QUANTO 1.2 software showed 98.0% power for rs1024611 to detect a relative risk difference between genotypes at the significance level of 0.05 and an odds ratio of 2.0 according to our sample size.
size. The chi-square or Fisher exact test was used to analyze the association between MCP-1 polymorphism and type 2 diabetes with sepsis, then we used Benjamini–Hochberg procedure for this multiple-testing correction to analyze the false discovery rate. Student t test or Mann–Whitney U test was performed to detect the difference between the means of 2 independent samples. The effects of diagnosis and MCP-1 variant on expression of MCP-1 gene and proinflammatory cytokines (TNF-α, IL-6, and IL-1β) were analyzed statistically by 2-way analysis of variance with post hoc Bonferroni correction of group means. A P value of <.05 was considered statistically significant.

3. Results

3.1. General clinical data of the included subjects

The basic clinical data of the subjects (113 cases in the T2DM combined with sepsis group and 172 cases in the T2DM group) are shown in Table 1. There was no statistical difference in age and gender distribution between the 2 groups. In the T2DM with sepsis group, the main source of infection was the respiratory tract (63.7%), gastrointestinal tract (16.8%), and bloodstream infection (15.0%), and the dominating pathogens are Acinetobacter baumannii (24.8%), Klebsiella pneumoniae (9.7%), and Staphylococcus aureus (8.8%); according to the sepsis 3.0 diagnostic criteria, the sepsis group was further divided into general sepsis group (67 cases) and septic shock group (46 cases). The 28-day ICU mortality rate was 29.2%.

3.2. The relationship between the polymorphism of MCP-1 rs1024611 and the susceptibility of T2DM with sepsis

The frequency distribution of rs1024611 genotype and alleles in the T2DM combined with the sepsis group and the T2DM control group are shown in Table 2. No significant deviation from Hardy–Weinberg equilibrium was detected for rs1024611 in both the sepsis and control groups (both P > .05). The genotype distributions between 2 groups were significantly different (P = .015). Compared with the control group, the frequency of rs1024611 AG/GG genotype in the T2DM combined with sepsis group was significantly higher than that in the control group (P = .004: AG + GG vs AA). The frequency of the rs1024611G allele was significantly higher in the diabetic combined with sepsis group than in the T2DM control group (P = .037).

3.3. Differences in the distribution of MCP-1 rs1024611 allele and genotype frequencies in different sepsis subgroups

Based on the severity of sepsis, we further divided 113 patients with T2DM with sepsis into the general sepsis group and septic shock group to assess the potential relationship between MCP-1 gene polymorphism and sepsis progression. As shown in the subgroup analysis in Table 3, the frequency of the rs1024611G allele in the T2DM with septic shock group was significantly higher than that in the T2DM with general sepsis group (P = .02), revealing that the rs1024611G allele may have a potential role in the progression of T2DM with sepsis from general sepsis to septic shock. Besides, T2DM patients with sepsis carrying GA/GG genotypes exhibited significantly higher Acute Physiology and Chronic Health Evaluation II score than those with AA genotype (P < .05).

3.4. The relationship between MCP-1 rs1024611 polymorphism and MCP-1 expression level

The location of the rs1024611 polymorphism in the promoter region of the MCP-1 gene is presented in Figure 1. We then randomly selected 24 patients with T2DM combined with sepsis and 36 patients with T2DM in the control group to detect the expression of MCP-1 mRNA in peripheral blood mononuclear cells. As shown in Figure 2, the expression level of MCP-1 mRNA in the T2DM combined with sepsis group was significantly higher than that in the control group (P < .001). In the sepsis subgroup, the expression of MCP-1 mRNA in the septic shock group was significantly higher than that in the general sepsis group (P < .05). In addition, we further evaluated the effects of different genotypes of MCP-1 rs1024611 on the expression of MCP-1 mRNA and found that the expression of GG genotype in the T2DM combined with the sepsis group was significantly higher than those in the control group (P < .001). In the sepsis subgroup, the expression levels of inflammatory factors in the septic shock group were significantly higher than those in the general sepsis group.

| Table 1 Clinical data of case group and control group. |
|------------------------------|------------------------------|
| Variable | T2DM and Sepsis (n = 113) N (%) | Control (n = 172) N (%) | P value |
| Demographics | | | |
| Age (yr), mean ± SD | 59.37 ± 16.1 | 56.56 ± 13.5 | .101 |
| Number (male/female) | 78/35 | 122/50 | .731 |
| Sepsis status, n (%) | | | |
| Mild sepsis | 67 (59.3) | NA | |
| Septic shock | 46 (40.7) | NA | |
| Source of infection, n (%) | | | |
| Respiratory tract infection | 72 (63.7) | NA | |
| Primary bloodstream infection | 17 (15.0) | NA | |
| Abdominal infection | 19 (16.8) | NA | |
| Urinary tract infection | 10 (8.8) | NA | |
| Catheter-associated infection | 6 (5.3) | NA | |
| Central nervous system infections | 9 (8.0) | NA | |
| Others | 14 (12.4) | NA | |
| Infection types, n (%) | | | |
| Acinetobacter baumannii | 28 (24.8) | NA | |
| Monilia albican | 9 (8.0) | NA | |
| Yeast sample sporphyte | 6 (5.3) | NA | |
| Aspergillus | 4 (3.5) | NA | |
| Klebsiella pneumoniae | 11 (9.7) | NA | |
| Pseudomonas aeruginosa | 9 (8.0) | NA | |
| Staphylococcus aureus | 10 (8.8) | NA | |
| Escherichia coli | 13 (11.5) | NA | |
| Others | 19 (16.8) | NA | |
| qSOGA score, mean ± SD | 2.53 ± 0.50 | NA | |
| Respiratory rate ≥22/min, n (%) | 103 (91.2) | NA | |
| Altered mentation, n (%) | 85 (75.2) | NA | |
| Systolic blood pressure ≤100 mm | 98 (86.7) | NA | |
| Hg, n (%) | | | |
| SOFA score, mean ± SD | 8.65 ± 4.68 | NA | |
| APACHE II score, mean ± SD | 24.3 ± 6.8 | NA | |
| 28-day mortality, n (%) | 33 (29.2) | NA | |

APACHE II = Acute Physiology and Chronic Health Evaluation II, NA = not applicable, qSOGA = quick sepsis-related organ dysfunction assessment, SBP = systolic blood pressure, SD = standard deviation, SOFA = sepsis-related organ dysfunction assessment, T2DM = type 2 diabetes mellitus.
Table 2
Distribution of genotype and allele frequency in case group and control group.

| MCP-1 | T2DM with sepsis, n = 113 (%) | Control, n = 172 (%) | P value | P value* | Odds ratio (95% CI) |
|-------|-----------------------------|----------------------|---------|----------|-------------------|
| Additive model | | | | | |
| AA | 19 (16.8) | 55 (32.0) | – | – | 1.000 (reference) |
| AG | 64 (56.6) | 76 (44.2) | 0.005 | 0.015 | 2.438 (1.313–4.525) |
| GG | 30 (26.5) | 41 (23.8) | 0.036 | 0.066 | 2.118 (1.049–4.277) |
| Additive model | | | | | |
| AA | 19 (16.8) | 55 (32.0) | 0.006 | 0.015 | 2.438 (1.313–4.525) |
| AG | 64 (56.6) | 76 (44.2) | 0.033 | 0.063 | 1.515 (0.847–2.684) |
| GG | 30 (26.5) | 41 (23.8) | – | – | 1.000 (reference) |
| Dominant model AA/AG vs GG | 83 (73.5) | 131 (76.2) | 0.505 | 0.563 | 1.000 (reference) |
| Recessive model AA vs AG/GG | 94 (83.2) | 117 (68.0) | 0.004 | 0.015 | 0.430 (0.239–0.774) |
| A allele | 102 (45.1) | 186 (54.1) | 0.037 | 0.060 | 1.431 (1.022–2.005) |
| G allele | 124 (54.9) | 158 (45.9) | – | – | 1.000 (reference) |
| HWE, P | 0.127 | 0.148 | – | – | – |

95% CI = 95% confidence interval, HWE = Hardy–Weinberg equilibrium, MCP-1 = monocyte chemoattractant protein-1, OR = odds ratio, T2DM = type 2 diabetes mellitus.
*False discovery rate-adjusted P value for multiple hypotheses testing using the Benjamin–Hochberg method.

Table 3
Genotype and allele frequency distribution of MCP-1 in different subgroups of sepsis with T2DM.

| MCP-1 | General sepsis, n = 67 (%) | Septic shock, n = 46 (%) | P value | P value* | Odds ratio (95% CI) |
|-------|-----------------------------|--------------------------|---------|----------|-------------------|
| Additive model | | | | | |
| AA | 15 (22.4) | 4 (8.7) | – | – | 1.000 (reference) |
| AG | 39 (58.2) | 25 (54.3) | 0.156 | 0.156 | 2.404 (0.715–8.076) |
| GG | 13 (19.4) | 17 (37.0) | 0.018 | 0.060 | 4.904 (1.312–18.326) |
| Additive model | | | | | |
| AA | 15 (22.4) | 4 (8.7) | 0.018 | 0.060 | 2.404 (0.715–8.076) |
| AG | 39 (58.2) | 25 (54.3) | 0.112 | 0.134 | 0.490 (0.203–1.181) |
| GG | 13 (19.4) | 17 (37.0) | – | – | 1.000 (reference) |
| Dominant model AA/AG vs GG | 54 (80.6) | 29 (63.0) | 0.051 | 0.102 | 2.435 (1.053–5.461) |
| Recessive model AA vs AG/GG | 15 (22.4) | 4 (8.7) | 0.074 | 0.111 | 0.330 (0.113–1.066) |
| A allele | 69 (51.5) | 33 (35.9) | – | – | 1.000 (reference) |
| G allele | 65 (48.5) | 59 (64.1) | 0.020 | 0.060 | 1.898 (1.101–3.271) |

95% CI = 95% confidence interval, MCP-1 = monocyte chemoattractant protein-1, OR = odds ratio, T2DM = type 2 diabetes mellitus.
*False discovery rate-adjusted P value for multiple hypotheses testing using the Benjamin–Hochberg method.

Figure 1. The promoter region of MCP-1 gene and the location of rs1024611 polymorphism. Human MCP-1 gene is located on human chromosome 17 (34,255,277–34,257,203). The blue bar represents the 5’ UTR of MCP-1 gene, and 3 dark green bars represent 3 exons, respectively. rs1024611 is located upstream of the transcription initiation site (-2518 BP). MCP-1 = monocyte chemoattractant protein-1, UTR = untranslated region.
In addition, compared with the rs1024611AA/GA genotype, the TNF-\(\alpha\) concentration in the carriers of the MCP-1 rs1024611GG genotype was significantly higher than that of the rs1024611AA/GA genotype (\(P < .05\)). However, the concentration of IL-6 and IL-1\(\beta\) of different genotypes was similar in the T2DM combined with sepsis group and control group.

4. Discussion

A number of studies indicate that genetic variation plays an important role in the occurrence and development of diseases,[20,21] in which MCP-1 single nucleotide polymorphism (SNP) has been widely reported to be related to T2DM, sepsis, and other inflammatory conditions.[22] In this study, we compared the allele frequency and genotype frequency of MCP-1 rs1024611 between the T2DM with sepsis group and the T2DM control in a case–control association analysis. The relationship between the rs1024611 polymorphism in the MCP-1 promoter region and the occurrence and development of T2DM with sepsis. The results showed that the ratio of rs1024611 AG/GG genotype frequency and G allele frequency in the T2DM with sepsis group was significantly higher than that in the control group. The ratio of rs1024611G allele frequency in the septic shock group was significantly higher than that of the general sepsis group. Our data suggest that MCP-1 SNP may serve as a risk factor for the occurrence and development of T2DM with sepsis.

The human MCP-1 gene located on chromosome 17q11.2-q12. MCP-1 plays a key role in regulating monocyte chemotaxis and endothelial activation, as well as regulating the progression of inflammation and the production of proinflammatory cytokines.[23] Lee et al.[24] have reported that the MCP-1 rs1024611 polymorphism is associated with Alzheimer disease,[24] asthma,[25] immunoglobulin A nephropathy,[26] lupus nephritis,[27] diabetic nephropathy,[28] and diabetic foot ulcer. Inhibition of MCP-1 or specific MCP-1 antagonist can inhibit the release of TNF-\(\alpha\), IL-1\(\beta\), and IL-6 in the T2DM combined with sepsis group were significantly higher than those in the control group, and the levels of these cytokines also increased with the severity of sepsis. More importantly, we observed that the plasma TNF-\(\alpha\) in patients with T2DM and sepsis carrying the rs1024611 GG genotype was upregulated with MCP-1. Although IL-1\(\beta\) and IL-6 did not increase simultaneously with MCP-1 as expected, this may be due to the small number of cases and the complex regulation of inflammatory response in the body. We infer that the rs1024611 G allele may increase the transcriptional activity of MCP-1 gene and upregulate the expression level of MCP-1, leading to overactivation of macrophages, increasing the production of proinflammatory cytokines, and ultimately leading to T2DM with sepsis. The detailed mechanism of the occurrence and development of the disease remains to be further studied.

There are certain limitations to this study. First, the small number of research subjects may affect our preliminary conclusions. Second, we only explored the relationship between the polymorphism of a single locus of the MCP-1 gene and T2DM with sepsis. The association of other functional polymorphisms with T2DM with sepsis needs to be further identified. Therefore, in the future, it is still necessary to increase the sample size of the study subjects and increase the detection of other functional polymorphisms of MCP-1 to verify the relationship between MCP-1 polymorphism and T2DM with sepsis.

5. Conclusions

In summary, this study proved for the first time that the MCP-1 gene polymorphism rs1024611 G allele/GG haplotype is related to the susceptibility and protection of T2DM with sepsis. The high-risk genotype GG of rs1024611 may increase the transcriptional activity of MCP-1 gene and upregulate the expression level of MCP-1, leading to overactivation of macrophages, increasing the production of proinflammatory cytokines, and ultimately leading to T2DM with sepsis. The detailed mechanism of the occurrence and development of the disease remains to be further studied.
Author contributions

Conceptualization: Yan Li, Junbing He, Yi-ming Shao, Yuhua Chen
Data curation: Yan Li, Junbing He
Formal analysis: Yan Li, Junbing He
Funding acquisition: Yi-ming Shao, Yuhua Chen
Investigation: Yan Li, Junbing He, Lanchun Chen, Ming Li, Donghui Tang, Zhizhou Shi, Qinghui Liao, Zhongqiu Guo, Juan Wang, Qiaoan Zheng, Yanni Zhao
Methodology: Lanchun Chen, Ming Li, Donghui Tang, Zhizhou Shi, Qinghui Liao, Zhongqiu Guo, Juan Wang, Qiaoan Zheng, Yanni Zhao
Project administration: Yi-ming Shao, Yuhua Chen
Resources: Yi-ming Shao, Yuhua Chen
Software: Yan Li, Junbing He
Supervision: Yi-ming Shao, Yuhua Chen

Validation: Yan Li, Junbing He
Visualization: Yan Li, Junbing He, Lanchun Chen, Ming Li, Donghui Tang, Zhizhou Shi, Qinghui Liao, Zhongqiu Guo, Juan Wang, Qiaoan Zheng, Yanni Zhao
Writing – original draft: Yan Li, Junbing He
Writing – review & editing: Yan Li, Junbing He, Yi-ming Shao, Yuhua Chen

References

[1] Van Vught LA, Scicluna BP, Hoogendijk AJ, et al. Association of diabetes and diabetes treatment with the host response in critically ill sepsis patients. Crit Care. 2016;20:252.
[2] Pasala SK, Rao AA, Sridhar GR. Built environment and diabetes. Int J Diabetes Dev Ctries. 2010;30:63–8.
[3] Lewis DH, Chan DL, Pinheiro D, et al. The immunopathology of sepsis: pathogen recognition, systemic inflammation, the compensatory...
anti-inflammatory response, and regulatory T cells. J Vet Intern Med. 2012;26:457–82.
[4] Esper AM, Moss M, Martin GS. The effect of diabetes mellitus on organ dysfunction with sepsis: an epidemiological study. Crit Care. 2009;13:R18.
[5] Finfer S, Chittock DR, Su SY, et al.; NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360:1283–97.
[6] Stacey HJ, Clements CS, Welburn SC, et al. The prevalence of methicillin-resistant Staphylococcus aureus among diabetic patients: a meta-analysis. Acta Diabetol. 2019;56:907–21.
[7] Moutzouri AG, Athanassiou GA, Dimitropoulou D, et al. Severe sepsis and diabetes mellitus have additive effects on red blood cell deformability. J Infect. 2008;57:147–51.
[8] Wang Z, Ren J, Wang G, et al. Association between diabetes mellitus and outcomes of patients with sepsis: a meta-analysis. Med Sci Monit. 2017;23:3546–55.
[9] Tiwari S, Pratyush DD, Gahlot A, et al. Sepsis in diabetes: a bad duo. Diabetes Metab Syndr. 2011;5:222–7.
[10] He J, Chen Y, Lin Y, et al. Association study of MCP-1 promoter polymorphisms with the susceptibility and progression of sepsis. PLoS One. 2017;12:e0176781.
[11] Bozzi Y, Caleo M. Epilepsy, seizures, and inflammation: role of the C-C motif ligand 2 chemokine. DNA Cell Biol. 2016;35:257–60.
[12] Yang M, Zhou X, Xu J, et al. Association of serum chemerin and inflammatory factors with type 2 diabetes macroangiopathy and waist-to-stature ratio. Bmn J Basic Med Sci. 2019;19:328–35.
[13] Thye T, Nejentsiev S, Intemann CD, et al. MCP-1 promoter variant -362C associated with protection from pulmonary tuberculosis in Ghana, West Africa. Hum Mol Genet. 2009;18:381–8.
[14] Guo C, Zhang H, Gao Q, et al. Monocyte chemotactrant protein-1 in spinal tuberculosis: -362G/C variant protein and protein levels in Chinese patients. Diagn Microbiol Infect Dis. 2014;78:49–52.
[15] Lin C, Wang Z, Shen L, et al. Genetic variants, circulating level of MCP1 with risk of chronic obstructive pulmonary disease: a case-control study. Pharmgenomics Pers Med. 2021;14:561–7.
[16] Palmieri O, Latiano A, Salvatori E, et al. The -A2518G polymorphism of monocyte chemotactrant protein-1 is associated with Crohn’s disease. Am J Gastroenterol. 2010;105:1586–94.
[17] Su N, Zhao N, Wang G, et al. Association of MCP-1 rs1024611 polymorphism with diabetic foot ulcers. Medicine (Baltimore). 2018;97:e11232.
[18] American Diabetes Association. Standards of medical care in diabetes-2016 abridged for primary care providers. Clin Diabetes. 2016;34:3–21.
[19] Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801–10.
[20] Zhao Y, Cui M, Gao Y, et al. Correlation of adiponectin gene +276 in exon 2 polymorphisms and type 2 diabetes mellitus in Chinese Han population: a meta-analysis. J Clin Med Practice. 2020;19:321–5.
[21] Ghafer MTA, Shalaby KH, Okda HI, et al. Association of ABCA1 (C69T) gene polymorphism with dyslipidemia and type 2 diabetes among the Egyptian population. Meta Gene. 2020;25:100714.
[22] Chen Z, Yin S, Zheng L, et al. Relationship between the monocyte chemotactrant protein-1 gene rs1024611 A>G polymorphism and cancer susceptibility: a meta-analysis involving 14,617 subjects. Immunol Invest. 2020;18:1–17.
[23] Han S, Li Z, Ji P, et al. MCP1P1 alleviated lipopolysaccharide-induced liver injury by regulating SIRT1 via modulation of microRNA-9. J Cell Physiol. 2019;234:22450–62.
[24] Lee WJ, Liao YC, Wang YF, et al. Plasma MCP-1 and cognitive decline in patients with Alzheimer’s disease and mild cognitive impairment: a two-year follow-up study. Sci Rep. 2018;8:1280.
[25] Chen W, Cui J, Xiang G, et al. Association between MCP-1 -2518A>G polymorphism and asthma susceptibility: a meta-analysis. Braz J Med Biol Res. 2019;52:e8549.
[26] Gao J, Liu X, Wei L, et al. Genetic variants of MCP-1 and CCR2 genes and IgA nephropathy risk. Oncotarget. 2016;7:77950–7.
[27] Zhou TB, Jiang ZP, Liang MJ, et al. Relationship between MCP-1 promoter-2518 A/G gene polymorphism (rs1024611) and systemic lupus erythematosus/lupus nephritis. J Recept Signal Transduct Res. 2015;35:85–93.
[28] Su N, Li HY, Huang MF, et al. Association of monocyte chemotactrant protein-1-2518G/A gene polymorphism with diabetic nephropathy risk. J Recept Signal Transduct Res. 2015;35:94–7.
[29] Li X. The association between MCP-1, VEGF polymorphisms and their serum levels in patients with diabetic foot ulcer. Medicine (Baltimore). 2018;97:e10959.